These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

250 related articles for article (PubMed ID: 15561734)

  • 21. [Presence of the antinuclear antibodies and antibodies to Borrelia burgdorferi among patients with morphea en plaque, deep linear scleroderma and atrophoderma Pasini-Pierini].
    Wojas-Pelc A; Wielowieyska-Szybińska D; Kiełtyka A
    Przegl Lek; 2002; 59(11):898-902. PubMed ID: 12715718
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Practice gaps: Evaluating the clinical utility of autoantibodies in morphea.
    Chiu YE
    JAMA Dermatol; 2013 Oct; 149(10):1166. PubMed ID: 23925297
    [No Abstract]   [Full Text] [Related]  

  • 23. [Thrombopenia associated to localized scleroderma].
    Rondón P; Aguilar A; Gallego M
    An Med Interna; 2001 Feb; 18(2):88-9. PubMed ID: 11322006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antinuclear antibodies and anti-DNA antibodies in scleroderma. A possible relationship between joint manifestations and increased antibodies in localized scleroderma.
    Serup J; Staun-Olsen P
    Allergy; 1986 Aug; 41(6):452-6. PubMed ID: 3491549
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antibodies to Th/To ribonucleoprotein in patients with localized scleroderma.
    Yamane K; Ihn H; Kubo M; Kuwana M; Asano Y; Yazawa N; Tamaki K
    Rheumatology (Oxford); 2001 Jun; 40(6):683-6. PubMed ID: 11426027
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Alternatively activated macrophages (M2 macrophages) in the skin of patient with localized scleroderma.
    Higashi-Kuwata N; Makino T; Inoue Y; Takeya M; Ihn H
    Exp Dermatol; 2009 Aug; 18(8):727-9. PubMed ID: 19320738
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Studies of the role of cellular immunity and angiogenetic changes in the pathogenesis of circumscribed scleroderma].
    Majewski S; Błaszczyk M; Chibowska M; Rosińska-Borkowska D; Kencka D; Rudnicka L; Marczak M; Makieła B; Skiendzielewska A; Jabłońska S
    Przegl Dermatol; 1990; 77(4):249-51. PubMed ID: 2267352
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Radiochemical demonstration of serum antibodies against double stranded DNA in progressive and circumscribed scleroderma].
    Meffert H; Falck P; Sönnichsen N
    Dermatol Wochenschr; 1975 Sep; 161(9):771-2. PubMed ID: 1081055
    [No Abstract]   [Full Text] [Related]  

  • 29. Expression of CD1a and CD86 on scleroderma Langerhans cells.
    Xie Y; Zhang X; Inoue Y; Wakasugi S; Makino T; Ihn H
    Eur J Dermatol; 2008; 18(1):50-4. PubMed ID: 18086589
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circulating Fc gamma receptor-specific autoantibodies in localized and systemic scleroderma.
    Davis K; Boros P; Keltz M; Unkeless JC; Fleischmajer R
    J Am Acad Dermatol; 1995 Oct; 33(4):612-6. PubMed ID: 7673494
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Localized scleroderma: a series of 52 patients.
    Toledano C; Rabhi S; Kettaneh A; Fabre B; Fardet L; Tiev KP; Cabane J
    Eur J Intern Med; 2009 May; 20(3):331-6. PubMed ID: 19393504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibodies against antigens related to scleroderma in a cohort of patients with morphea.
    Arisi M; Cavazzana I; Cerutti ME; Ferrari F; Carabellese N; Rossi MT; Tincani A; Calzavara-Pinton P; Franceschini F
    G Ital Dermatol Venereol; 2018 Aug; 153(4):451-458. PubMed ID: 27706114
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Laboratory diagnosis of polysystemic autoimmune diseases].
    Sipka S
    Orv Hetil; 2005 Feb; 146(9):403-9. PubMed ID: 15830607
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum autoantibodies and their clinical associations in patients with childhood- and adult-onset linear scleroderma. A single-center study.
    Arkachaisri T; Fertig N; Pino S; Medsger TA
    J Rheumatol; 2008 Dec; 35(12):2439-44. PubMed ID: 19004036
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A case of linear scleroderma and myasthenia gravis.
    Kim HS; Chun YS; Hann SK; Park WH
    J Dermatol; 2000 Jan; 27(1):31-4. PubMed ID: 10692822
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Anti-topoisomerase I autoantibodies in systemic sclerosis.
    Czömpöly T; Simon D; Czirják L; Németh P
    Autoimmun Rev; 2009 Jul; 8(8):692-6. PubMed ID: 19393194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Types of anticellular structure antisera in scleroderma patients].
    Ni ZM
    Zhonghua Yi Xue Za Zhi; 1993 May; 73(5):270-2, 318. PubMed ID: 8221243
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Pathogenesis of skin scleroderma--literature review].
    Wojas-Pelc A; Lipko-Godlewska S
    Przegl Lek; 2005; 62(5):310-3. PubMed ID: 16334538
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The presence of dominant T-cell clones in peripheral blood of patients with collagen vascular disorders: a prospective study of 97 cases.
    Dereure O; Gubler B; Bessis D; Guillot B; Guilhou JJ; Clot J; Eliaou JF
    Br J Dermatol; 2006 Mar; 154(3):445-9. PubMed ID: 16445773
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multiplexed AtheNA multi-lyte immunoassay for ANA screening in autoimmune diseases.
    Shovman O; Gilburd B; Zandman-Goddard G; Yehiely A; Langevitz P; Shoenfeld Y
    Autoimmunity; 2005 Feb; 38(1):105-9. PubMed ID: 15804711
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.